178 filings
8-K
ARAV
Aravive Inc
17 Jan 24
Entry into a Material Definitive Agreement
4:22pm
8-K
ARAV
Aravive Inc
3 Nov 23
Amendments to Articles of Incorporation or Bylaws
4:05pm
8-K
ARAV
Aravive Inc
3 Oct 23
Submission of Matters to a Vote of Security Holders
4:05pm
8-K
ARAV
Aravive Inc
19 Sep 23
Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard
4:10pm
8-K
ARAV
Aravive Inc
2 Aug 23
Aravive Announces Top-Line Results from Phase 3 AXLerate-OC Study of Batiraxcept in Platinum-Resistant Ovarian Cancer
4:18pm
8-K
c0jy2anbty ysfg
5 Jun 23
Regulation FD Disclosure
4:05pm
8-K
18emmis5b6b1 6u37
25 May 23
Regulation FD Disclosure
5:00pm
8-K
lb9s wqvlt
16 May 23
Aravive Announces Phase 3 Trial Design for Batiraxcept in Clear Cell Renal Cell Carcinoma
7:05am
8-K
vncwp5
10 May 23
Aravive Reports First Quarter 2023 Financial Results and Provides Corporate Updates
4:05pm
8-K
o68qbpxipy 3dvq
11 Apr 23
Aravive Appoints Carolina Petrini as Chief Commercial Officer
7:10am
8-K
mogmzs 6y2zoysecu
15 Mar 23
Aravive Reports Fourth Quarter and Full Year 2022 Financial Results and Provides Corporate Updates
7:10am
8-K
6l4vq45a6 exb8hp1fl5
28 Feb 23
Aravive Announces FDA Orphan Drug Designation Granted to Batiraxcept for the Treatment of Pancreatic Cancer
4:11pm
8-K
nw6ybur3ddk c50onr
13 Feb 23
Regulation FD Disclosure
5:06pm
8-K
rzt 1bigtxg
6 Feb 23
Departure of Directors or Certain Officers
5:09pm
8-K
3b3st jze
18 Jan 23
Amendments to Articles of Incorporation or Bylaws
4:05pm
8-K
ricuhif76b5y zl3yr7
4 Jan 23
Aravive Announces Complete Enrollment in the Global Registrational Phase 3 AXLerate-OC Trial for Platinum-Resistant Ovarian Cancer
7:05am
8-K
4u8qkzus1f5c1 kzvo0
3 Jan 23
Other Events
4:06pm
8-K
pzwyytr4g
29 Nov 22
Aravive Announces Fast Track Designation of Batiraxcept for Treatment of ccRCC
7:05am
8-K
mpw2rg ttw
16 Nov 22
Other Events
7:05am
8-K
sjby 33kasy
10 Nov 22
Aravive Reports Third Quarter 2022 Financial Results and Provides Corporate Updates
7:05am